Novavax CEO: 'We're Going to Make a Significant Impact on This COVID Pandemic'_老虎社区_美港股上老虎

Novavax CEO: 'We're Going to Make a Significant Impact on This COVID Pandemic'

Yahoo Finance2022-01-13

Novavax (NVAX) is waiting for its COVID-19 vaccine to be authorized in the U.S., but with authorizations now in three major markets globally, the biotech company says it's making its mark on the ...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

XLMM
·2022-01-13
cant wait for their earning report...
回复
点赞
举报
RO8
·2022-01-13
Yes
回复
点赞
举报
股惑仔79
·2022-01-13
[What]
回复
2
举报

热议股票

7x24

全部

{"i18n":{"language":"zh_CN"},"data":{"share":"https://www.laohu8.com/m/news/1107505154?lang=zh_CN&edition=full","thumbnail":"","is_english":true,"pubTime":"2022-01-13 08:59","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1107505154","market":"us","top_or_hot":-1,"title":"Novavax CEO: 'We're Going to Make a Significant Impact on This COVID Pandemic'","media":"Yahoo Finance","content":"<div>\nNovavax (NVAX) is waiting for its COVID-19 vaccine to be authorized in the U.S., but with authorizations now in three major markets globally, the biotech company says it's making its mark on the ...\n\n<a href=\"https://finance.yahoo.com/news/novavax-ceo-were-going-to-make-a-significant-impact-on-this-covid-pandemic-195631610.html\">网页链接</a>\n\n</div>\n","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Novavax CEO: 'We're Going to Make a Significant Impact on This COVID Pandemic'</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNovavax CEO: 'We're Going to Make a Significant Impact on This COVID Pandemic'\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-01-13 08:59 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/novavax-ceo-were-going-to-make-a-significant-impact-on-this-covid-pandemic-195631610.html>Yahoo Finance</a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\nNovavax (NVAX) is waiting for its COVID-19 vaccine to be authorized in the U.S., but with authorizations now in three major markets globally, the biotech company says it's making its mark on the ...\n\n<a href=\"https://finance.yahoo.com/news/novavax-ceo-were-going-to-make-a-significant-impact-on-this-covid-pandemic-195631610.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"NVAX","symbol_name":"诺瓦瓦克斯医药","start_time":0,"source_url":"https://finance.yahoo.com/news/novavax-ceo-were-going-to-make-a-significant-impact-on-this-covid-pandemic-195631610.html","article_id":"1107505154","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1107505154","pubTimestamp":1642035550,"columns":[],"sourceInfo":null,"weMediaInfo":null,"summary":"Novavax (NVAX) is waiting for its COVID-19 vaccine to be authorized in the U.S., but with authorizat","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"NVAX":"诺瓦瓦克斯医药"},"translate_title":"诺瓦瓦克斯医药首席执行官：“我们将对这场COVID流行病产生重大影响”","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NVAX":0.9},"content_text":"Novavax (NVAX) is waiting for its COVID-19 vaccine to be authorized in the U.S., but with authorizations now in three major markets globally, the biotech company says it's making its mark on the pandemic.\"We're going to make a significant impact on this Covid pandemic,\" CEO Stanley Erck told Yahoo Finance Tuesday.\"The market for primary vaccination — two-dose vaccination which is now being talked about as three-dose vaccination — is unsatisfied,\" Erck said.\"It's not exclusively low income countries, because high income countries need this. We need to get past the vaccine hesitancy,\" he added.If the definition for 'fully-vaccinated' changes to three doses, for both Novavax and mRNA vaccines, it could mean a complete reset in vaccination completions globally.Erck, who spoke at the JPMorgan annual health care conference this week, says the company is going to meet a production speed of 200 million doses per month by the end of the first quarter.It has already begun shipments to Europe, which should total 27 million by the end of the first quarter, as well as a batch of 10 million doses to Indonesia — the site of its first shots in arms.Chief commercial officer John Trizzino told Yahoo Finance that Novavax wasn't going to provide specific guidance on the total number of doses for the year, largely because it is still waiting for more authorizations to come through, which would impact the total doses.As of Tuesday, Novavax has received use authorization in Indonesia, India, Europe and the Philippines, and emergency use listing from the World Health Organization. It is still awaiting authorization in South Africa, Australia, New Zealand, Singapore, Japan, UAE, U.K. and Canada. It is also waiting to get the green light to file for emergency use with the U.S. Food and Drug Administration, after submitting the necessary data at the end of 2021.Through the WHO emergency listing, the company's vaccine is now available to 170 countries.\"We worked really hard over the past two years ... and now it's time to introduce our product to the world,\" Trizzino said.Manufacturing hurdlesNovavax was a struggling late-stage biotech when the pandemic started, but it pivoted to focus on the pandemic with the help of global philanthropies and the U.S. government.The company was working on a Phase 3 clinical trial for its flu vaccine and had failed to bring an RSV vaccine to market.\"We, because of our RSV failures prior to that, we basically started with no manufacturing capacity. So, you're starting out in the hole, if you will, and we had to scale up very, very quickly,\" Trizzino said.The company's manufacturing problems contributed significantly to a delayed timeline in the past year. Trizzino said it was a significant challenge to have to manage eight global sites at one time.\"Why didn't we just focus on one facility and slam dunk it? Well, what would have been the right facility to pick? So, it was more effort than we had assumed to tech transfer to multiple facilities,\" he said.In addition, the vaccine platform, while it offers easy to store and transport benefits, is complicated to make.\"It's a complicated assay, and we underestimated what it would take to develop those assays,\" Trizzino said.Normally, it would have taken the company four to six years to scale up to where it has in the past two, he said.Now, a partnership with the Serum Institute of India — which is also producing AstraZeneca's (AZN) vaccine— is helping the company make up for lost time.In fact, if the vaccine is authorized in the U.S., it will be based off of the same data sent to other global health authorities, relying on the Serum Institute's manufacturing quality for doses.\"So it would be Serum product that we would use in the U.S.,\" Trizzino said, noting that while the company is U.S.-based, its \"success or failure as a company...is not exclusively based in the U.S.\"Global vaccine marketTrizzino said that the company's global focus does not mean the company will be only a provider to low income countries.\"People misunderstand the market. It's not the typical vaccine launch where in year one we get launched in the U.S., and two or three years later it gets launched in Europe, and three to five years later it gets launched to the rest of the world. It's all at once,\" Trizzino said.The company lost an opportunity to play a major role in the initial wave of vaccines in the U.S., but it still has a small market — as the country hovers at 66%of the eligible population fully vaccinated — as well opportunity globally.Trizzino said that represents a 180 million dose opportunity in primary doses alone in the U.S. Add to that primary doses and boosters globally and the total is a 4 billion dose opportunity.The potential doesn't stop there, Trizzino said, noting there could be additional boosters or annual revaccination on the table.\"Now, we're not saying we're going to capture all that. But what people should take away is that the trend line is that there's an increase in demand for vaccines, not a decrease,\" Trizzino added.The pricing strategy, meanwhile, does not reflects traditional tiered rollout of vaccines, where the U.S. can end up paying double what Europe pays. Instead, the pricing is based on a country's ability to pay.\"Basically, Europe and the U.S. are paying the same price for doses right now. So people kind of need to reset their expectations about the way that they think about the commercial market, and what the demand profile looks like,\" Trizzino said.","kind":"news","is_publish_news":true,"is_publish_highlight":true,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[{"id":694436535,"gmtCreate":1642070803449,"gmtModify":1642070803511,"author":{"id":"4100909250192760","authorId":"4100909250192760","name":"XLMM","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":11,"crmLevelSwitch":0,"authorIdStr":"4100909250192760","idStr":"4100909250192760"},"htmlText":"cant wait for their earning report...","listText":"cant wait for their earning report...","text":"cant wait for their earning report...","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/694436535","repostId":1107505154,"repostType":2,"repost":{"id":"1107505154","kind":"news","pubTimestamp":1642035550,"share":"https://www.laohu8.com/m/news/1107505154?lang=zh_CN&edition=full","pubTime":"2022-01-13 08:59","market":"us","language":"en","title":"Novavax CEO: 'We're Going to Make a Significant Impact on This COVID Pandemic'<blockquote>Novavax首席执行官：“我们将对这场新冠疫情产生重大影响”</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1107505154","media":"Yahoo Finance","summary":"Novavax (NVAX) is waiting for its COVID-19 vaccine to be authorized in the U.S., but with authorizat","content":"<html><head></head><body>Novavax (NVAX) is waiting for its COVID-19 vaccine to be authorized in the U.S., but with authorizations now in three major markets globally, the biotech company says it&#39;s making its mark on the pandemic.<blockquote><html><head></head><body>Novavax(NVAX)正在等待其COVID-19疫苗在美国获得授权，但随着目前已在全球三个主要市场获得授权，这家生物技术公司表示，它正在这一流行病上留下印记。</body></html></blockquote>&#34;We&#39;re going to make a significant impact on this Covid pandemic,&#34; CEO Stanley Erck told Yahoo Finance Tuesday.<blockquote>首席执行官斯坦利·埃尔克周二对雅虎财经表示：“我们将对这场新冠疫情产生重大影响。”</blockquote>&#34;The market for primary vaccination — two-dose vaccination which is now being talked about as three-dose vaccination — is unsatisfied,&#34; Erck said.<blockquote>埃尔克说：“初级疫苗接种——两剂疫苗接种，现在被称为三剂疫苗接种——的市场并不满意。”</blockquote>&#34;It&#39;s not exclusively low income countries, because high income countries need this. We need to get past the vaccine hesitancy,&#34; he added.<blockquote>“这不仅仅是低收入国家，因为高收入国家需要这个。我们需要克服疫苗犹豫，”他补充道。</blockquote>If the definition for &#39;fully-vaccinated&#39; changes to three doses, for both Novavax and mRNA vaccines, it could mean a complete reset in vaccination completions globally.<blockquote>如果Novavax和mRNA疫苗的“完全接种”定义更改为三剂，这可能意味着全球疫苗接种完成量的完全重置。</blockquote>Erck, who spoke at the JPMorgan annual health care conference this week, says the company is going to meet a production speed of 200 million doses per month by the end of the first quarter.<blockquote>埃尔克本周在摩根大通年度医疗保健会议上发表讲话时表示，该公司将在第一季度末达到每月2亿剂的生产速度。</blockquote>It has already begun shipments to Europe, which should total 27 million by the end of the first quarter, as well as a batch of 10 million doses to Indonesia — the site of its first shots in arms.<blockquote>它已经开始向欧洲发货，到第一季度末，总量将达到2700万剂，并向印度尼西亚发货1000万剂，印度尼西亚是它第一次打响武器的地方。</blockquote>Chief commercial officer John Trizzino told Yahoo Finance that Novavax wasn&#39;t going to provide specific guidance on the total number of doses for the year, largely because it is still waiting for more authorizations to come through, which would impact the total doses.<blockquote>首席商务官John Trizzino告诉雅虎财经，Novavax不会就今年的总剂量提供具体指导，主要是因为它仍在等待更多授权的通过，这将影响总剂量。</blockquote>As of Tuesday, Novavax has received use authorization in Indonesia, India, Europe and the Philippines, and emergency use listing from the World Health Organization. It is still awaiting authorization in South Africa, Australia, New Zealand, Singapore, Japan, UAE, U.K. and Canada. It is also waiting to get the green light to file for emergency use with the U.S. Food and Drug Administration, after submitting the necessary data at the end of 2021.<blockquote>截至周二，Novavax已获得印度尼西亚、印度、欧洲和菲律宾的使用授权，以及世界卫生组织的紧急使用清单。它仍在等待南非、澳大利亚、新西兰、新加坡、日本、阿联酋、英国和加拿大的授权。它还在等待向美国申请紧急使用的批准。食品药品监督管理局，在2021年底提交必要数据后。</blockquote>Through the WHO emergency listing, the company&#39;s vaccine is now available to 170 countries.<blockquote>通过世卫组织紧急上市，该公司的疫苗现已可供170个国家使用。</blockquote>&#34;We worked really hard over the past two years ... and now it&#39;s time to introduce our product to the world,&#34; Trizzino said.<blockquote>“过去两年我们非常努力……现在是时候向世界介绍我们的产品了，”特里齐诺说。</blockquote>Manufacturing hurdles<blockquote>制造障碍</blockquote>Novavax was a struggling late-stage biotech when the pandemic started, but it pivoted to focus on the pandemic with the help of global philanthropies and the U.S. government.<blockquote>当疫情开始时，Novavax是一家苦苦挣扎的后期生物技术公司，但在全球慈善机构和美国政府的帮助下，它转向专注于疫情。</blockquote>The company was working on a Phase 3 clinical trial for its flu vaccine and had failed to bring an RSV vaccine to market.<blockquote>该公司正在进行流感疫苗的3期临床试验，但未能将RSV疫苗推向市场。</blockquote>&#34;We, because of our RSV failures prior to that, we basically started with no manufacturing capacity. So, you&#39;re starting out in the hole, if you will, and we had to scale up very, very quickly,&#34; Trizzino said.<blockquote>“由于在此之前的RSV故障，我们基本上一开始就没有制造能力。所以，如果你愿意的话，你就从洞里开始，我们必须非常非常快地扩大规模，”特里齐诺说。</blockquote>The company&#39;s manufacturing problems contributed significantly to a delayed timeline in the past year. Trizzino said it was a significant challenge to have to manage eight global sites at one time.<blockquote>该公司的制造问题在很大程度上导致了过去一年的时间表推迟。Trizzino表示，必须同时管理八个全球站点是一个重大挑战。</blockquote>&#34;Why didn&#39;t we just focus on one facility and slam dunk it? Well, what would have been the right facility to pick? So, it was more effort than we had assumed to tech transfer to multiple facilities,&#34; he said.<blockquote>“为什么我们不专注于一个设施并大功告成呢？那么，选择什么设施才是正确的？因此，将技术转移到多个设施比我们想象的要付出更多的努力，”他说。</blockquote>In addition, the vaccine platform, while it offers easy to store and transport benefits, is complicated to make.<blockquote>此外，疫苗平台虽然具有易于储存和运输的优点，但制造起来很复杂。</blockquote>&#34;It&#39;s a complicated assay, and we underestimated what it would take to develop those assays,&#34; Trizzino said.<blockquote>“这是一种复杂的检测方法，我们低估了开发这些检测方法所需的费用，”特里齐诺说。</blockquote>Normally, it would have taken the company four to six years to scale up to where it has in the past two, he said.<blockquote>他说，通常情况下，该公司需要四到六年的时间才能扩大到过去两年的规模。</blockquote>Now, a partnership with the Serum Institute of India — which is also producing AstraZeneca&#39;s (AZN) vaccine— is helping the company make up for lost time.<blockquote>现在，与印度血清研究所（该研究所也生产阿斯利康（AZN）疫苗）的合作正在帮助该公司弥补失去的时间。</blockquote>In fact, if the vaccine is authorized in the U.S., it will be based off of the same data sent to other global health authorities, relying on the Serum Institute&#39;s manufacturing quality for doses.<blockquote>事实上，如果该疫苗在美国获得授权，它将基于发送给其他全球卫生当局的相同数据，依赖于血清研究所的剂量制造质量。</blockquote>&#34;So it would be Serum product that we would use in the U.S.,&#34; Trizzino said, noting that while the company is U.S.-based, its &#34;success or failure as a company...is not exclusively based in the U.S.&#34;<blockquote>特里齐诺说：“因此，我们将在美国使用血清产品。”他指出，虽然该公司总部位于美国，但其“作为一家公司的成功或失败……并不完全取决于美国。”</blockquote>Global vaccine market<blockquote>全球疫苗市场</blockquote>Trizzino said that the company&#39;s global focus does not mean the company will be only a provider to low income countries.<blockquote>Trizzino表示，该公司专注于全球并不意味着该公司将只是低收入国家的供应商。</blockquote>&#34;People misunderstand the market. It&#39;s not the typical vaccine launch where in year one we get launched in the U.S., and two or three years later it gets launched in Europe, and three to five years later it gets launched to the rest of the world. It&#39;s all at once,&#34; Trizzino said.<blockquote>“人们误解了市场。这不是典型的疫苗发布，第一年我们在美国上市，两三年后在欧洲上市，三到五年后在世界其他地方上市。这一切都是一次性的，”特里齐诺说。</blockquote>The company lost an opportunity to play a major role in the initial wave of vaccines in the U.S., but it still has a small market — as the country hovers at 66%of the eligible population fully vaccinated — as well opportunity globally.<blockquote>该公司失去了在美国第一波疫苗中发挥重要作用的机会，但它仍然有一个小市场——因为该国完全接种疫苗的合格人口的比例徘徊在66%——以及全球机会。</blockquote>Trizzino said that represents a 180 million dose opportunity in primary doses alone in the U.S. Add to that primary doses and boosters globally and the total is a 4 billion dose opportunity.<blockquote>Trizzino表示，仅在美国，仅初级剂量就有1.8亿剂的机会。再加上全球范围内的初级剂量和加强剂量，总共有40亿剂的机会。</blockquote>The potential doesn&#39;t stop there, Trizzino said, noting there could be additional boosters or annual revaccination on the table.<blockquote>Trizzino说，潜力还不止于此，并指出可能会有额外的加强剂或每年重新接种疫苗。</blockquote>&#34;Now, we&#39;re not saying we&#39;re going to capture all that. But what people should take away is that the trend line is that there&#39;s an increase in demand for vaccines, not a decrease,&#34; Trizzino added.<blockquote>“现在，我们并不是说我们会抓住所有这些。但人们应该记住的是，趋势线是对疫苗的需求增加，而不是减少，”特里齐诺补充道。</blockquote>The pricing strategy, meanwhile, does not reflects traditional tiered rollout of vaccines, where the U.S. can end up paying double what Europe pays. Instead, the pricing is based on a country&#39;s ability to pay.<blockquote>与此同时，定价策略并没有反映传统的疫苗分级推出，美国最终可能支付欧洲两倍的费用。相反，定价是基于一个国家的支付能力。</blockquote>&#34;Basically, Europe and the U.S. are paying the same price for doses right now. So people kind of need to reset their expectations about the way that they think about the commercial market, and what the demand profile looks like,&#34; Trizzino said.<blockquote>“基本上，欧洲和美国目前为剂量支付的价格相同。因此，人们需要重新设定他们对商业市场的看法以及需求状况的预期，”特里齐诺说。</blockquote></body></html><blockquote></blockquote>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Novavax CEO: 'We're Going to Make a Significant Impact on This COVID Pandemic'<blockquote>Novavax首席执行官：“我们将对这场新冠疫情产生重大影响”</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNovavax CEO: 'We're Going to Make a Significant Impact on This COVID Pandemic'<blockquote>Novavax首席执行官：“我们将对这场新冠疫情产生重大影响”</blockquote>\n</h2>\n<h4 class=\"meta\">\n\nYahoo Finance2022-01-13 08:59\n\n</h4>\n</header>\n<article>\n<html><head></head><body>Novavax (NVAX) is waiting for its COVID-19 vaccine to be authorized in the U.S., but with authorizations now in three major markets globally, the biotech company says it&#39;s making its mark on the pandemic.<blockquote><html><head></head><body>Novavax(NVAX)正在等待其COVID-19疫苗在美国获得授权，但随着目前已在全球三个主要市场获得授权，这家生物技术公司表示，它正在这一流行病上留下印记。</body></html></blockquote>&#34;We&#39;re going to make a significant impact on this Covid pandemic,&#34; CEO Stanley Erck told Yahoo Finance Tuesday.<blockquote>首席执行官斯坦利·埃尔克周二对雅虎财经表示：“我们将对这场新冠疫情产生重大影响。”</blockquote>&#34;The market for primary vaccination — two-dose vaccination which is now being talked about as three-dose vaccination — is unsatisfied,&#34; Erck said.<blockquote>埃尔克说：“初级疫苗接种——两剂疫苗接种，现在被称为三剂疫苗接种——的市场并不满意。”</blockquote>&#34;It&#39;s not exclusively low income countries, because high income countries need this. We need to get past the vaccine hesitancy,&#34; he added.<blockquote>“这不仅仅是低收入国家，因为高收入国家需要这个。我们需要克服疫苗犹豫，”他补充道。</blockquote>If the definition for &#39;fully-vaccinated&#39; changes to three doses, for both Novavax and mRNA vaccines, it could mean a complete reset in vaccination completions globally.<blockquote>如果Novavax和mRNA疫苗的“完全接种”定义更改为三剂，这可能意味着全球疫苗接种完成量的完全重置。</blockquote>Erck, who spoke at the JPMorgan annual health care conference this week, says the company is going to meet a production speed of 200 million doses per month by the end of the first quarter.<blockquote>埃尔克本周在摩根大通年度医疗保健会议上发表讲话时表示，该公司将在第一季度末达到每月2亿剂的生产速度。</blockquote>It has already begun shipments to Europe, which should total 27 million by the end of the first quarter, as well as a batch of 10 million doses to Indonesia — the site of its first shots in arms.<blockquote>它已经开始向欧洲发货，到第一季度末，总量将达到2700万剂，并向印度尼西亚发货1000万剂，印度尼西亚是它第一次打响武器的地方。</blockquote>Chief commercial officer John Trizzino told Yahoo Finance that Novavax wasn&#39;t going to provide specific guidance on the total number of doses for the year, largely because it is still waiting for more authorizations to come through, which would impact the total doses.<blockquote>首席商务官John Trizzino告诉雅虎财经，Novavax不会就今年的总剂量提供具体指导，主要是因为它仍在等待更多授权的通过，这将影响总剂量。</blockquote>As of Tuesday, Novavax has received use authorization in Indonesia, India, Europe and the Philippines, and emergency use listing from the World Health Organization. It is still awaiting authorization in South Africa, Australia, New Zealand, Singapore, Japan, UAE, U.K. and Canada. It is also waiting to get the green light to file for emergency use with the U.S. Food and Drug Administration, after submitting the necessary data at the end of 2021.<blockquote>截至周二，Novavax已获得印度尼西亚、印度、欧洲和菲律宾的使用授权，以及世界卫生组织的紧急使用清单。它仍在等待南非、澳大利亚、新西兰、新加坡、日本、阿联酋、英国和加拿大的授权。它还在等待向美国申请紧急使用的批准。食品药品监督管理局，在2021年底提交必要数据后。</blockquote>Through the WHO emergency listing, the company&#39;s vaccine is now available to 170 countries.<blockquote>通过世卫组织紧急上市，该公司的疫苗现已可供170个国家使用。</blockquote>&#34;We worked really hard over the past two years ... and now it&#39;s time to introduce our product to the world,&#34; Trizzino said.<blockquote>“过去两年我们非常努力……现在是时候向世界介绍我们的产品了，”特里齐诺说。</blockquote>Manufacturing hurdles<blockquote>制造障碍</blockquote>Novavax was a struggling late-stage biotech when the pandemic started, but it pivoted to focus on the pandemic with the help of global philanthropies and the U.S. government.<blockquote>当疫情开始时，Novavax是一家苦苦挣扎的后期生物技术公司，但在全球慈善机构和美国政府的帮助下，它转向专注于疫情。</blockquote>The company was working on a Phase 3 clinical trial for its flu vaccine and had failed to bring an RSV vaccine to market.<blockquote>该公司正在进行流感疫苗的3期临床试验，但未能将RSV疫苗推向市场。</blockquote>&#34;We, because of our RSV failures prior to that, we basically started with no manufacturing capacity. So, you&#39;re starting out in the hole, if you will, and we had to scale up very, very quickly,&#34; Trizzino said.<blockquote>“由于在此之前的RSV故障，我们基本上一开始就没有制造能力。所以，如果你愿意的话，你就从洞里开始，我们必须非常非常快地扩大规模，”特里齐诺说。</blockquote>The company&#39;s manufacturing problems contributed significantly to a delayed timeline in the past year. Trizzino said it was a significant challenge to have to manage eight global sites at one time.<blockquote>该公司的制造问题在很大程度上导致了过去一年的时间表推迟。Trizzino表示，必须同时管理八个全球站点是一个重大挑战。</blockquote>&#34;Why didn&#39;t we just focus on one facility and slam dunk it? Well, what would have been the right facility to pick? So, it was more effort than we had assumed to tech transfer to multiple facilities,&#34; he said.<blockquote>“为什么我们不专注于一个设施并大功告成呢？那么，选择什么设施才是正确的？因此，将技术转移到多个设施比我们想象的要付出更多的努力，”他说。</blockquote>In addition, the vaccine platform, while it offers easy to store and transport benefits, is complicated to make.<blockquote>此外，疫苗平台虽然具有易于储存和运输的优点，但制造起来很复杂。</blockquote>&#34;It&#39;s a complicated assay, and we underestimated what it would take to develop those assays,&#34; Trizzino said.<blockquote>“这是一种复杂的检测方法，我们低估了开发这些检测方法所需的费用，”特里齐诺说。</blockquote>Normally, it would have taken the company four to six years to scale up to where it has in the past two, he said.<blockquote>他说，通常情况下，该公司需要四到六年的时间才能扩大到过去两年的规模。</blockquote>Now, a partnership with the Serum Institute of India — which is also producing AstraZeneca&#39;s (AZN) vaccine— is helping the company make up for lost time.<blockquote>现在，与印度血清研究所（该研究所也生产阿斯利康（AZN）疫苗）的合作正在帮助该公司弥补失去的时间。</blockquote>In fact, if the vaccine is authorized in the U.S., it will be based off of the same data sent to other global health authorities, relying on the Serum Institute&#39;s manufacturing quality for doses.<blockquote>事实上，如果该疫苗在美国获得授权，它将基于发送给其他全球卫生当局的相同数据，依赖于血清研究所的剂量制造质量。</blockquote>&#34;So it would be Serum product that we would use in the U.S.,&#34; Trizzino said, noting that while the company is U.S.-based, its &#34;success or failure as a company...is not exclusively based in the U.S.&#34;<blockquote>特里齐诺说：“因此，我们将在美国使用血清产品。”他指出，虽然该公司总部位于美国，但其“作为一家公司的成功或失败……并不完全取决于美国。”</blockquote>Global vaccine market<blockquote>全球疫苗市场</blockquote>Trizzino said that the company&#39;s global focus does not mean the company will be only a provider to low income countries.<blockquote>Trizzino表示，该公司专注于全球并不意味着该公司将只是低收入国家的供应商。</blockquote>&#34;People misunderstand the market. It&#39;s not the typical vaccine launch where in year one we get launched in the U.S., and two or three years later it gets launched in Europe, and three to five years later it gets launched to the rest of the world. It&#39;s all at once,&#34; Trizzino said.<blockquote>“人们误解了市场。这不是典型的疫苗发布，第一年我们在美国上市，两三年后在欧洲上市，三到五年后在世界其他地方上市。这一切都是一次性的，”特里齐诺说。</blockquote>The company lost an opportunity to play a major role in the initial wave of vaccines in the U.S., but it still has a small market — as the country hovers at 66%of the eligible population fully vaccinated — as well opportunity globally.<blockquote>该公司失去了在美国第一波疫苗中发挥重要作用的机会，但它仍然有一个小市场——因为该国完全接种疫苗的合格人口的比例徘徊在66%——以及全球机会。</blockquote>Trizzino said that represents a 180 million dose opportunity in primary doses alone in the U.S. Add to that primary doses and boosters globally and the total is a 4 billion dose opportunity.<blockquote>Trizzino表示，仅在美国，仅初级剂量就有1.8亿剂的机会。再加上全球范围内的初级剂量和加强剂量，总共有40亿剂的机会。</blockquote>The potential doesn&#39;t stop there, Trizzino said, noting there could be additional boosters or annual revaccination on the table.<blockquote>Trizzino说，潜力还不止于此，并指出可能会有额外的加强剂或每年重新接种疫苗。</blockquote>&#34;Now, we&#39;re not saying we&#39;re going to capture all that. But what people should take away is that the trend line is that there&#39;s an increase in demand for vaccines, not a decrease,&#34; Trizzino added.<blockquote>“现在，我们并不是说我们会抓住所有这些。但人们应该记住的是，趋势线是对疫苗的需求增加，而不是减少，”特里齐诺补充道。</blockquote>The pricing strategy, meanwhile, does not reflects traditional tiered rollout of vaccines, where the U.S. can end up paying double what Europe pays. Instead, the pricing is based on a country&#39;s ability to pay.<blockquote>与此同时，定价策略并没有反映传统的疫苗分级推出，美国最终可能支付欧洲两倍的费用。相反，定价是基于一个国家的支付能力。</blockquote>&#34;Basically, Europe and the U.S. are paying the same price for doses right now. So people kind of need to reset their expectations about the way that they think about the commercial market, and what the demand profile looks like,&#34; Trizzino said.<blockquote>“基本上，欧洲和美国目前为剂量支付的价格相同。因此，人们需要重新设定他们对商业市场的看法以及需求状况的预期，”特里齐诺说。</blockquote></body></html><blockquote></blockquote>\n<div class=\"bt-text\">\n\n\n 来源：<a href=\"https://finance.yahoo.com/news/novavax-ceo-were-going-to-make-a-significant-impact-on-this-covid-pandemic-195631610.html\">Yahoo Finance</a>\n为提升您的阅读体验，我们对本页面进行了排版优化\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NVAX":"诺瓦瓦克斯医药"},"source_url":"https://finance.yahoo.com/news/novavax-ceo-were-going-to-make-a-significant-impact-on-this-covid-pandemic-195631610.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1107505154","content_text":"Novavax (NVAX) is waiting for its COVID-19 vaccine to be authorized in the U.S., but with authorizations now in three major markets globally, the biotech company says it's making its mark on the pandemic.\"We're going to make a significant impact on this Covid pandemic,\" CEO Stanley Erck told Yahoo Finance Tuesday.\"The market for primary vaccination — two-dose vaccination which is now being talked about as three-dose vaccination — is unsatisfied,\" Erck said.\"It's not exclusively low income countries, because high income countries need this. We need to get past the vaccine hesitancy,\" he added.If the definition for 'fully-vaccinated' changes to three doses, for both Novavax and mRNA vaccines, it could mean a complete reset in vaccination completions globally.Erck, who spoke at the JPMorgan annual health care conference this week, says the company is going to meet a production speed of 200 million doses per month by the end of the first quarter.It has already begun shipments to Europe, which should total 27 million by the end of the first quarter, as well as a batch of 10 million doses to Indonesia — the site of its first shots in arms.Chief commercial officer John Trizzino told Yahoo Finance that Novavax wasn't going to provide specific guidance on the total number of doses for the year, largely because it is still waiting for more authorizations to come through, which would impact the total doses.As of Tuesday, Novavax has received use authorization in Indonesia, India, Europe and the Philippines, and emergency use listing from the World Health Organization. It is still awaiting authorization in South Africa, Australia, New Zealand, Singapore, Japan, UAE, U.K. and Canada. It is also waiting to get the green light to file for emergency use with the U.S. Food and Drug Administration, after submitting the necessary data at the end of 2021.Through the WHO emergency listing, the company's vaccine is now available to 170 countries.\"We worked really hard over the past two years ... and now it's time to introduce our product to the world,\" Trizzino said.Manufacturing hurdlesNovavax was a struggling late-stage biotech when the pandemic started, but it pivoted to focus on the pandemic with the help of global philanthropies and the U.S. government.The company was working on a Phase 3 clinical trial for its flu vaccine and had failed to bring an RSV vaccine to market.\"We, because of our RSV failures prior to that, we basically started with no manufacturing capacity. So, you're starting out in the hole, if you will, and we had to scale up very, very quickly,\" Trizzino said.The company's manufacturing problems contributed significantly to a delayed timeline in the past year. Trizzino said it was a significant challenge to have to manage eight global sites at one time.\"Why didn't we just focus on one facility and slam dunk it? Well, what would have been the right facility to pick? So, it was more effort than we had assumed to tech transfer to multiple facilities,\" he said.In addition, the vaccine platform, while it offers easy to store and transport benefits, is complicated to make.\"It's a complicated assay, and we underestimated what it would take to develop those assays,\" Trizzino said.Normally, it would have taken the company four to six years to scale up to where it has in the past two, he said.Now, a partnership with the Serum Institute of India — which is also producing AstraZeneca's (AZN) vaccine— is helping the company make up for lost time.In fact, if the vaccine is authorized in the U.S., it will be based off of the same data sent to other global health authorities, relying on the Serum Institute's manufacturing quality for doses.\"So it would be Serum product that we would use in the U.S.,\" Trizzino said, noting that while the company is U.S.-based, its \"success or failure as a company...is not exclusively based in the U.S.\"Global vaccine marketTrizzino said that the company's global focus does not mean the company will be only a provider to low income countries.\"People misunderstand the market. It's not the typical vaccine launch where in year one we get launched in the U.S., and two or three years later it gets launched in Europe, and three to five years later it gets launched to the rest of the world. It's all at once,\" Trizzino said.The company lost an opportunity to play a major role in the initial wave of vaccines in the U.S., but it still has a small market — as the country hovers at 66%of the eligible population fully vaccinated — as well opportunity globally.Trizzino said that represents a 180 million dose opportunity in primary doses alone in the U.S. Add to that primary doses and boosters globally and the total is a 4 billion dose opportunity.The potential doesn't stop there, Trizzino said, noting there could be additional boosters or annual revaccination on the table.\"Now, we're not saying we're going to capture all that. But what people should take away is that the trend line is that there's an increase in demand for vaccines, not a decrease,\" Trizzino added.The pricing strategy, meanwhile, does not reflects traditional tiered rollout of vaccines, where the U.S. can end up paying double what Europe pays. Instead, the pricing is based on a country's ability to pay.\"Basically, Europe and the U.S. are paying the same price for doses right now. So people kind of need to reset their expectations about the way that they think about the commercial market, and what the demand profile looks like,\" Trizzino said.","news_type":1,"symbols_score_info":{"NVAX":0.9}},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"},{"id":694532206,"gmtCreate":1642040912729,"gmtModify":1642040913003,"author":{"id":"3585981947031986","authorId":"3585981947031986","name":"RO8","avatar":"https://static.tigerbbs.com/1f744cb66900b3865c3ed1da7364ddce","vip":1,"crmLevel":11,"crmLevelSwitch":0,"authorIdStr":"3585981947031986","idStr":"3585981947031986"},"htmlText":"Yes","listText":"Yes","text":"Yes","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/694532206","repostId":1107505154,"repostType":4,"repost":{"id":"1107505154","kind":"news","pubTimestamp":1642035550,"share":"https://www.laohu8.com/m/news/1107505154?lang=zh_CN&edition=full","pubTime":"2022-01-13 08:59","market":"us","language":"en","title":"Novavax CEO: 'We're Going to Make a Significant Impact on This COVID Pandemic'<blockquote>Novavax首席执行官：“我们将对这场新冠疫情产生重大影响”</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1107505154","media":"Yahoo Finance","summary":"Novavax (NVAX) is waiting for its COVID-19 vaccine to be authorized in the U.S., but with authorizat","content":"<html><head></head><body>Novavax (NVAX) is waiting for its COVID-19 vaccine to be authorized in the U.S., but with authorizations now in three major markets globally, the biotech company says it&#39;s making its mark on the pandemic.<blockquote><html><head></head><body>Novavax(NVAX)正在等待其COVID-19疫苗在美国获得授权，但随着目前已在全球三个主要市场获得授权，这家生物技术公司表示，它正在这一流行病上留下印记。</body></html></blockquote>&#34;We&#39;re going to make a significant impact on this Covid pandemic,&#34; CEO Stanley Erck told Yahoo Finance Tuesday.<blockquote>首席执行官斯坦利·埃尔克周二对雅虎财经表示：“我们将对这场新冠疫情产生重大影响。”</blockquote>&#34;The market for primary vaccination — two-dose vaccination which is now being talked about as three-dose vaccination — is unsatisfied,&#34; Erck said.<blockquote>埃尔克说：“初级疫苗接种——两剂疫苗接种，现在被称为三剂疫苗接种——的市场并不满意。”</blockquote>&#34;It&#39;s not exclusively low income countries, because high income countries need this. We need to get past the vaccine hesitancy,&#34; he added.<blockquote>“这不仅仅是低收入国家，因为高收入国家需要这个。我们需要克服疫苗犹豫，”他补充道。</blockquote>If the definition for &#39;fully-vaccinated&#39; changes to three doses, for both Novavax and mRNA vaccines, it could mean a complete reset in vaccination completions globally.<blockquote>如果Novavax和mRNA疫苗的“完全接种”定义更改为三剂，这可能意味着全球疫苗接种完成量的完全重置。</blockquote>Erck, who spoke at the JPMorgan annual health care conference this week, says the company is going to meet a production speed of 200 million doses per month by the end of the first quarter.<blockquote>埃尔克本周在摩根大通年度医疗保健会议上发表讲话时表示，该公司将在第一季度末达到每月2亿剂的生产速度。</blockquote>It has already begun shipments to Europe, which should total 27 million by the end of the first quarter, as well as a batch of 10 million doses to Indonesia — the site of its first shots in arms.<blockquote>它已经开始向欧洲发货，到第一季度末，总量将达到2700万剂，并向印度尼西亚发货1000万剂，印度尼西亚是它第一次打响武器的地方。</blockquote>Chief commercial officer John Trizzino told Yahoo Finance that Novavax wasn&#39;t going to provide specific guidance on the total number of doses for the year, largely because it is still waiting for more authorizations to come through, which would impact the total doses.<blockquote>首席商务官John Trizzino告诉雅虎财经，Novavax不会就今年的总剂量提供具体指导，主要是因为它仍在等待更多授权的通过，这将影响总剂量。</blockquote>As of Tuesday, Novavax has received use authorization in Indonesia, India, Europe and the Philippines, and emergency use listing from the World Health Organization. It is still awaiting authorization in South Africa, Australia, New Zealand, Singapore, Japan, UAE, U.K. and Canada. It is also waiting to get the green light to file for emergency use with the U.S. Food and Drug Administration, after submitting the necessary data at the end of 2021.<blockquote>截至周二，Novavax已获得印度尼西亚、印度、欧洲和菲律宾的使用授权，以及世界卫生组织的紧急使用清单。它仍在等待南非、澳大利亚、新西兰、新加坡、日本、阿联酋、英国和加拿大的授权。它还在等待向美国申请紧急使用的批准。食品药品监督管理局，在2021年底提交必要数据后。</blockquote>Through the WHO emergency listing, the company&#39;s vaccine is now available to 170 countries.<blockquote>通过世卫组织紧急上市，该公司的疫苗现已可供170个国家使用。</blockquote>&#34;We worked really hard over the past two years ... and now it&#39;s time to introduce our product to the world,&#34; Trizzino said.<blockquote>“过去两年我们非常努力……现在是时候向世界介绍我们的产品了，”特里齐诺说。</blockquote>Manufacturing hurdles<blockquote>制造障碍</blockquote>Novavax was a struggling late-stage biotech when the pandemic started, but it pivoted to focus on the pandemic with the help of global philanthropies and the U.S. government.<blockquote>当疫情开始时，Novavax是一家苦苦挣扎的后期生物技术公司，但在全球慈善机构和美国政府的帮助下，它转向专注于疫情。</blockquote>The company was working on a Phase 3 clinical trial for its flu vaccine and had failed to bring an RSV vaccine to market.<blockquote>该公司正在进行流感疫苗的3期临床试验，但未能将RSV疫苗推向市场。</blockquote>&#34;We, because of our RSV failures prior to that, we basically started with no manufacturing capacity. So, you&#39;re starting out in the hole, if you will, and we had to scale up very, very quickly,&#34; Trizzino said.<blockquote>“由于在此之前的RSV故障，我们基本上一开始就没有制造能力。所以，如果你愿意的话，你就从洞里开始，我们必须非常非常快地扩大规模，”特里齐诺说。</blockquote>The company&#39;s manufacturing problems contributed significantly to a delayed timeline in the past year. Trizzino said it was a significant challenge to have to manage eight global sites at one time.<blockquote>该公司的制造问题在很大程度上导致了过去一年的时间表推迟。Trizzino表示，必须同时管理八个全球站点是一个重大挑战。</blockquote>&#34;Why didn&#39;t we just focus on one facility and slam dunk it? Well, what would have been the right facility to pick? So, it was more effort than we had assumed to tech transfer to multiple facilities,&#34; he said.<blockquote>“为什么我们不专注于一个设施并大功告成呢？那么，选择什么设施才是正确的？因此，将技术转移到多个设施比我们想象的要付出更多的努力，”他说。</blockquote>In addition, the vaccine platform, while it offers easy to store and transport benefits, is complicated to make.<blockquote>此外，疫苗平台虽然具有易于储存和运输的优点，但制造起来很复杂。</blockquote>&#34;It&#39;s a complicated assay, and we underestimated what it would take to develop those assays,&#34; Trizzino said.<blockquote>“这是一种复杂的检测方法，我们低估了开发这些检测方法所需的费用，”特里齐诺说。</blockquote>Normally, it would have taken the company four to six years to scale up to where it has in the past two, he said.<blockquote>他说，通常情况下，该公司需要四到六年的时间才能扩大到过去两年的规模。</blockquote>Now, a partnership with the Serum Institute of India — which is also producing AstraZeneca&#39;s (AZN) vaccine— is helping the company make up for lost time.<blockquote>现在，与印度血清研究所（该研究所也生产阿斯利康（AZN）疫苗）的合作正在帮助该公司弥补失去的时间。</blockquote>In fact, if the vaccine is authorized in the U.S., it will be based off of the same data sent to other global health authorities, relying on the Serum Institute&#39;s manufacturing quality for doses.<blockquote>事实上，如果该疫苗在美国获得授权，它将基于发送给其他全球卫生当局的相同数据，依赖于血清研究所的剂量制造质量。</blockquote>&#34;So it would be Serum product that we would use in the U.S.,&#34; Trizzino said, noting that while the company is U.S.-based, its &#34;success or failure as a company...is not exclusively based in the U.S.&#34;<blockquote>特里齐诺说：“因此，我们将在美国使用血清产品。”他指出，虽然该公司总部位于美国，但其“作为一家公司的成功或失败……并不完全取决于美国。”</blockquote>Global vaccine market<blockquote>全球疫苗市场</blockquote>Trizzino said that the company&#39;s global focus does not mean the company will be only a provider to low income countries.<blockquote>Trizzino表示，该公司专注于全球并不意味着该公司将只是低收入国家的供应商。</blockquote>&#34;People misunderstand the market. It&#39;s not the typical vaccine launch where in year one we get launched in the U.S., and two or three years later it gets launched in Europe, and three to five years later it gets launched to the rest of the world. It&#39;s all at once,&#34; Trizzino said.<blockquote>“人们误解了市场。这不是典型的疫苗发布，第一年我们在美国上市，两三年后在欧洲上市，三到五年后在世界其他地方上市。这一切都是一次性的，”特里齐诺说。</blockquote>The company lost an opportunity to play a major role in the initial wave of vaccines in the U.S., but it still has a small market — as the country hovers at 66%of the eligible population fully vaccinated — as well opportunity globally.<blockquote>该公司失去了在美国第一波疫苗中发挥重要作用的机会，但它仍然有一个小市场——因为该国完全接种疫苗的合格人口的比例徘徊在66%——以及全球机会。</blockquote>Trizzino said that represents a 180 million dose opportunity in primary doses alone in the U.S. Add to that primary doses and boosters globally and the total is a 4 billion dose opportunity.<blockquote>Trizzino表示，仅在美国，仅初级剂量就有1.8亿剂的机会。再加上全球范围内的初级剂量和加强剂量，总共有40亿剂的机会。</blockquote>The potential doesn&#39;t stop there, Trizzino said, noting there could be additional boosters or annual revaccination on the table.<blockquote>Trizzino说，潜力还不止于此，并指出可能会有额外的加强剂或每年重新接种疫苗。</blockquote>&#34;Now, we&#39;re not saying we&#39;re going to capture all that. But what people should take away is that the trend line is that there&#39;s an increase in demand for vaccines, not a decrease,&#34; Trizzino added.<blockquote>“现在，我们并不是说我们会抓住所有这些。但人们应该记住的是，趋势线是对疫苗的需求增加，而不是减少，”特里齐诺补充道。</blockquote>The pricing strategy, meanwhile, does not reflects traditional tiered rollout of vaccines, where the U.S. can end up paying double what Europe pays. Instead, the pricing is based on a country&#39;s ability to pay.<blockquote>与此同时，定价策略并没有反映传统的疫苗分级推出，美国最终可能支付欧洲两倍的费用。相反，定价是基于一个国家的支付能力。</blockquote>&#34;Basically, Europe and the U.S. are paying the same price for doses right now. So people kind of need to reset their expectations about the way that they think about the commercial market, and what the demand profile looks like,&#34; Trizzino said.<blockquote>“基本上，欧洲和美国目前为剂量支付的价格相同。因此，人们需要重新设定他们对商业市场的看法以及需求状况的预期，”特里齐诺说。</blockquote></body></html><blockquote></blockquote>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Novavax CEO: 'We're Going to Make a Significant Impact on This COVID Pandemic'<blockquote>Novavax首席执行官：“我们将对这场新冠疫情产生重大影响”</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNovavax CEO: 'We're Going to Make a Significant Impact on This COVID Pandemic'<blockquote>Novavax首席执行官：“我们将对这场新冠疫情产生重大影响”</blockquote>\n</h2>\n<h4 class=\"meta\">\n\nYahoo Finance2022-01-13 08:59\n\n</h4>\n</header>\n<article>\n<html><head></head><body>Novavax (NVAX) is waiting for its COVID-19 vaccine to be authorized in the U.S., but with authorizations now in three major markets globally, the biotech company says it&#39;s making its mark on the pandemic.<blockquote><html><head></head><body>Novavax(NVAX)正在等待其COVID-19疫苗在美国获得授权，但随着目前已在全球三个主要市场获得授权，这家生物技术公司表示，它正在这一流行病上留下印记。</body></html></blockquote>&#34;We&#39;re going to make a significant impact on this Covid pandemic,&#34; CEO Stanley Erck told Yahoo Finance Tuesday.<blockquote>首席执行官斯坦利·埃尔克周二对雅虎财经表示：“我们将对这场新冠疫情产生重大影响。”</blockquote>&#34;The market for primary vaccination — two-dose vaccination which is now being talked about as three-dose vaccination — is unsatisfied,&#34; Erck said.<blockquote>埃尔克说：“初级疫苗接种——两剂疫苗接种，现在被称为三剂疫苗接种——的市场并不满意。”</blockquote>&#34;It&#39;s not exclusively low income countries, because high income countries need this. We need to get past the vaccine hesitancy,&#34; he added.<blockquote>“这不仅仅是低收入国家，因为高收入国家需要这个。我们需要克服疫苗犹豫，”他补充道。</blockquote>If the definition for &#39;fully-vaccinated&#39; changes to three doses, for both Novavax and mRNA vaccines, it could mean a complete reset in vaccination completions globally.<blockquote>如果Novavax和mRNA疫苗的“完全接种”定义更改为三剂，这可能意味着全球疫苗接种完成量的完全重置。</blockquote>Erck, who spoke at the JPMorgan annual health care conference this week, says the company is going to meet a production speed of 200 million doses per month by the end of the first quarter.<blockquote>埃尔克本周在摩根大通年度医疗保健会议上发表讲话时表示，该公司将在第一季度末达到每月2亿剂的生产速度。</blockquote>It has already begun shipments to Europe, which should total 27 million by the end of the first quarter, as well as a batch of 10 million doses to Indonesia — the site of its first shots in arms.<blockquote>它已经开始向欧洲发货，到第一季度末，总量将达到2700万剂，并向印度尼西亚发货1000万剂，印度尼西亚是它第一次打响武器的地方。</blockquote>Chief commercial officer John Trizzino told Yahoo Finance that Novavax wasn&#39;t going to provide specific guidance on the total number of doses for the year, largely because it is still waiting for more authorizations to come through, which would impact the total doses.<blockquote>首席商务官John Trizzino告诉雅虎财经，Novavax不会就今年的总剂量提供具体指导，主要是因为它仍在等待更多授权的通过，这将影响总剂量。</blockquote>As of Tuesday, Novavax has received use authorization in Indonesia, India, Europe and the Philippines, and emergency use listing from the World Health Organization. It is still awaiting authorization in South Africa, Australia, New Zealand, Singapore, Japan, UAE, U.K. and Canada. It is also waiting to get the green light to file for emergency use with the U.S. Food and Drug Administration, after submitting the necessary data at the end of 2021.<blockquote>截至周二，Novavax已获得印度尼西亚、印度、欧洲和菲律宾的使用授权，以及世界卫生组织的紧急使用清单。它仍在等待南非、澳大利亚、新西兰、新加坡、日本、阿联酋、英国和加拿大的授权。它还在等待向美国申请紧急使用的批准。食品药品监督管理局，在2021年底提交必要数据后。</blockquote>Through the WHO emergency listing, the company&#39;s vaccine is now available to 170 countries.<blockquote>通过世卫组织紧急上市，该公司的疫苗现已可供170个国家使用。</blockquote>&#34;We worked really hard over the past two years ... and now it&#39;s time to introduce our product to the world,&#34; Trizzino said.<blockquote>“过去两年我们非常努力……现在是时候向世界介绍我们的产品了，”特里齐诺说。</blockquote>Manufacturing hurdles<blockquote>制造障碍</blockquote>Novavax was a struggling late-stage biotech when the pandemic started, but it pivoted to focus on the pandemic with the help of global philanthropies and the U.S. government.<blockquote>当疫情开始时，Novavax是一家苦苦挣扎的后期生物技术公司，但在全球慈善机构和美国政府的帮助下，它转向专注于疫情。</blockquote>The company was working on a Phase 3 clinical trial for its flu vaccine and had failed to bring an RSV vaccine to market.<blockquote>该公司正在进行流感疫苗的3期临床试验，但未能将RSV疫苗推向市场。</blockquote>&#34;We, because of our RSV failures prior to that, we basically started with no manufacturing capacity. So, you&#39;re starting out in the hole, if you will, and we had to scale up very, very quickly,&#34; Trizzino said.<blockquote>“由于在此之前的RSV故障，我们基本上一开始就没有制造能力。所以，如果你愿意的话，你就从洞里开始，我们必须非常非常快地扩大规模，”特里齐诺说。</blockquote>The company&#39;s manufacturing problems contributed significantly to a delayed timeline in the past year. Trizzino said it was a significant challenge to have to manage eight global sites at one time.<blockquote>该公司的制造问题在很大程度上导致了过去一年的时间表推迟。Trizzino表示，必须同时管理八个全球站点是一个重大挑战。</blockquote>&#34;Why didn&#39;t we just focus on one facility and slam dunk it? Well, what would have been the right facility to pick? So, it was more effort than we had assumed to tech transfer to multiple facilities,&#34; he said.<blockquote>“为什么我们不专注于一个设施并大功告成呢？那么，选择什么设施才是正确的？因此，将技术转移到多个设施比我们想象的要付出更多的努力，”他说。</blockquote>In addition, the vaccine platform, while it offers easy to store and transport benefits, is complicated to make.<blockquote>此外，疫苗平台虽然具有易于储存和运输的优点，但制造起来很复杂。</blockquote>&#34;It&#39;s a complicated assay, and we underestimated what it would take to develop those assays,&#34; Trizzino said.<blockquote>“这是一种复杂的检测方法，我们低估了开发这些检测方法所需的费用，”特里齐诺说。</blockquote>Normally, it would have taken the company four to six years to scale up to where it has in the past two, he said.<blockquote>他说，通常情况下，该公司需要四到六年的时间才能扩大到过去两年的规模。</blockquote>Now, a partnership with the Serum Institute of India — which is also producing AstraZeneca&#39;s (AZN) vaccine— is helping the company make up for lost time.<blockquote>现在，与印度血清研究所（该研究所也生产阿斯利康（AZN）疫苗）的合作正在帮助该公司弥补失去的时间。</blockquote>In fact, if the vaccine is authorized in the U.S., it will be based off of the same data sent to other global health authorities, relying on the Serum Institute&#39;s manufacturing quality for doses.<blockquote>事实上，如果该疫苗在美国获得授权，它将基于发送给其他全球卫生当局的相同数据，依赖于血清研究所的剂量制造质量。</blockquote>&#34;So it would be Serum product that we would use in the U.S.,&#34; Trizzino said, noting that while the company is U.S.-based, its &#34;success or failure as a company...is not exclusively based in the U.S.&#34;<blockquote>特里齐诺说：“因此，我们将在美国使用血清产品。”他指出，虽然该公司总部位于美国，但其“作为一家公司的成功或失败……并不完全取决于美国。”</blockquote>Global vaccine market<blockquote>全球疫苗市场</blockquote>Trizzino said that the company&#39;s global focus does not mean the company will be only a provider to low income countries.<blockquote>Trizzino表示，该公司专注于全球并不意味着该公司将只是低收入国家的供应商。</blockquote>&#34;People misunderstand the market. It&#39;s not the typical vaccine launch where in year one we get launched in the U.S., and two or three years later it gets launched in Europe, and three to five years later it gets launched to the rest of the world. It&#39;s all at once,&#34; Trizzino said.<blockquote>“人们误解了市场。这不是典型的疫苗发布，第一年我们在美国上市，两三年后在欧洲上市，三到五年后在世界其他地方上市。这一切都是一次性的，”特里齐诺说。</blockquote>The company lost an opportunity to play a major role in the initial wave of vaccines in the U.S., but it still has a small market — as the country hovers at 66%of the eligible population fully vaccinated — as well opportunity globally.<blockquote>该公司失去了在美国第一波疫苗中发挥重要作用的机会，但它仍然有一个小市场——因为该国完全接种疫苗的合格人口的比例徘徊在66%——以及全球机会。</blockquote>Trizzino said that represents a 180 million dose opportunity in primary doses alone in the U.S. Add to that primary doses and boosters globally and the total is a 4 billion dose opportunity.<blockquote>Trizzino表示，仅在美国，仅初级剂量就有1.8亿剂的机会。再加上全球范围内的初级剂量和加强剂量，总共有40亿剂的机会。</blockquote>The potential doesn&#39;t stop there, Trizzino said, noting there could be additional boosters or annual revaccination on the table.<blockquote>Trizzino说，潜力还不止于此，并指出可能会有额外的加强剂或每年重新接种疫苗。</blockquote>&#34;Now, we&#39;re not saying we&#39;re going to capture all that. But what people should take away is that the trend line is that there&#39;s an increase in demand for vaccines, not a decrease,&#34; Trizzino added.<blockquote>“现在，我们并不是说我们会抓住所有这些。但人们应该记住的是，趋势线是对疫苗的需求增加，而不是减少，”特里齐诺补充道。</blockquote>The pricing strategy, meanwhile, does not reflects traditional tiered rollout of vaccines, where the U.S. can end up paying double what Europe pays. Instead, the pricing is based on a country&#39;s ability to pay.<blockquote>与此同时，定价策略并没有反映传统的疫苗分级推出，美国最终可能支付欧洲两倍的费用。相反，定价是基于一个国家的支付能力。</blockquote>&#34;Basically, Europe and the U.S. are paying the same price for doses right now. So people kind of need to reset their expectations about the way that they think about the commercial market, and what the demand profile looks like,&#34; Trizzino said.<blockquote>“基本上，欧洲和美国目前为剂量支付的价格相同。因此，人们需要重新设定他们对商业市场的看法以及需求状况的预期，”特里齐诺说。</blockquote></body></html><blockquote></blockquote>\n<div class=\"bt-text\">\n\n\n 来源：<a href=\"https://finance.yahoo.com/news/novavax-ceo-were-going-to-make-a-significant-impact-on-this-covid-pandemic-195631610.html\">Yahoo Finance</a>\n为提升您的阅读体验，我们对本页面进行了排版优化\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NVAX":"诺瓦瓦克斯医药"},"source_url":"https://finance.yahoo.com/news/novavax-ceo-were-going-to-make-a-significant-impact-on-this-covid-pandemic-195631610.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1107505154","content_text":"Novavax (NVAX) is waiting for its COVID-19 vaccine to be authorized in the U.S., but with authorizations now in three major markets globally, the biotech company says it's making its mark on the pandemic.\"We're going to make a significant impact on this Covid pandemic,\" CEO Stanley Erck told Yahoo Finance Tuesday.\"The market for primary vaccination — two-dose vaccination which is now being talked about as three-dose vaccination — is unsatisfied,\" Erck said.\"It's not exclusively low income countries, because high income countries need this. We need to get past the vaccine hesitancy,\" he added.If the definition for 'fully-vaccinated' changes to three doses, for both Novavax and mRNA vaccines, it could mean a complete reset in vaccination completions globally.Erck, who spoke at the JPMorgan annual health care conference this week, says the company is going to meet a production speed of 200 million doses per month by the end of the first quarter.It has already begun shipments to Europe, which should total 27 million by the end of the first quarter, as well as a batch of 10 million doses to Indonesia — the site of its first shots in arms.Chief commercial officer John Trizzino told Yahoo Finance that Novavax wasn't going to provide specific guidance on the total number of doses for the year, largely because it is still waiting for more authorizations to come through, which would impact the total doses.As of Tuesday, Novavax has received use authorization in Indonesia, India, Europe and the Philippines, and emergency use listing from the World Health Organization. It is still awaiting authorization in South Africa, Australia, New Zealand, Singapore, Japan, UAE, U.K. and Canada. It is also waiting to get the green light to file for emergency use with the U.S. Food and Drug Administration, after submitting the necessary data at the end of 2021.Through the WHO emergency listing, the company's vaccine is now available to 170 countries.\"We worked really hard over the past two years ... and now it's time to introduce our product to the world,\" Trizzino said.Manufacturing hurdlesNovavax was a struggling late-stage biotech when the pandemic started, but it pivoted to focus on the pandemic with the help of global philanthropies and the U.S. government.The company was working on a Phase 3 clinical trial for its flu vaccine and had failed to bring an RSV vaccine to market.\"We, because of our RSV failures prior to that, we basically started with no manufacturing capacity. So, you're starting out in the hole, if you will, and we had to scale up very, very quickly,\" Trizzino said.The company's manufacturing problems contributed significantly to a delayed timeline in the past year. Trizzino said it was a significant challenge to have to manage eight global sites at one time.\"Why didn't we just focus on one facility and slam dunk it? Well, what would have been the right facility to pick? So, it was more effort than we had assumed to tech transfer to multiple facilities,\" he said.In addition, the vaccine platform, while it offers easy to store and transport benefits, is complicated to make.\"It's a complicated assay, and we underestimated what it would take to develop those assays,\" Trizzino said.Normally, it would have taken the company four to six years to scale up to where it has in the past two, he said.Now, a partnership with the Serum Institute of India — which is also producing AstraZeneca's (AZN) vaccine— is helping the company make up for lost time.In fact, if the vaccine is authorized in the U.S., it will be based off of the same data sent to other global health authorities, relying on the Serum Institute's manufacturing quality for doses.\"So it would be Serum product that we would use in the U.S.,\" Trizzino said, noting that while the company is U.S.-based, its \"success or failure as a company...is not exclusively based in the U.S.\"Global vaccine marketTrizzino said that the company's global focus does not mean the company will be only a provider to low income countries.\"People misunderstand the market. It's not the typical vaccine launch where in year one we get launched in the U.S., and two or three years later it gets launched in Europe, and three to five years later it gets launched to the rest of the world. It's all at once,\" Trizzino said.The company lost an opportunity to play a major role in the initial wave of vaccines in the U.S., but it still has a small market — as the country hovers at 66%of the eligible population fully vaccinated — as well opportunity globally.Trizzino said that represents a 180 million dose opportunity in primary doses alone in the U.S. Add to that primary doses and boosters globally and the total is a 4 billion dose opportunity.The potential doesn't stop there, Trizzino said, noting there could be additional boosters or annual revaccination on the table.\"Now, we're not saying we're going to capture all that. But what people should take away is that the trend line is that there's an increase in demand for vaccines, not a decrease,\" Trizzino added.The pricing strategy, meanwhile, does not reflects traditional tiered rollout of vaccines, where the U.S. can end up paying double what Europe pays. Instead, the pricing is based on a country's ability to pay.\"Basically, Europe and the U.S. are paying the same price for doses right now. So people kind of need to reset their expectations about the way that they think about the commercial market, and what the demand profile looks like,\" Trizzino said.","news_type":1,"symbols_score_info":{"NVAX":0.9}},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"},{"id":694599737,"gmtCreate":1642036658843,"gmtModify":1642036659542,"author":{"id":"3577415105079753","authorId":"3577415105079753","name":"股惑仔79","avatar":"https://static.tigerbbs.com/2521bf7235578dd93b9e7d10c59d5058","vip":1,"crmLevel":11,"crmLevelSwitch":0,"authorIdStr":"3577415105079753","idStr":"3577415105079753"},"htmlText":"[What]&nbsp;","listText":"[What]&nbsp;","text":"[What]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/694599737","repostId":1107505154,"repostType":4,"repost":{"id":"1107505154","kind":"news","pubTimestamp":1642035550,"share":"https://www.laohu8.com/m/news/1107505154?lang=zh_CN&edition=full","pubTime":"2022-01-13 08:59","market":"us","language":"en","title":"Novavax CEO: 'We're Going to Make a Significant Impact on This COVID Pandemic'<blockquote>Novavax首席执行官：“我们将对这场新冠疫情产生重大影响”</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1107505154","media":"Yahoo Finance","summary":"Novavax (NVAX) is waiting for its COVID-19 vaccine to be authorized in the U.S., but with authorizat","content":"<html><head></head><body>Novavax (NVAX) is waiting for its COVID-19 vaccine to be authorized in the U.S., but with authorizations now in three major markets globally, the biotech company says it&#39;s making its mark on the pandemic.<blockquote><html><head></head><body>Novavax(NVAX)正在等待其COVID-19疫苗在美国获得授权，但随着目前已在全球三个主要市场获得授权，这家生物技术公司表示，它正在这一流行病上留下印记。</body></html></blockquote>&#34;We&#39;re going to make a significant impact on this Covid pandemic,&#34; CEO Stanley Erck told Yahoo Finance Tuesday.<blockquote>首席执行官斯坦利·埃尔克周二对雅虎财经表示：“我们将对这场新冠疫情产生重大影响。”</blockquote>&#34;The market for primary vaccination — two-dose vaccination which is now being talked about as three-dose vaccination — is unsatisfied,&#34; Erck said.<blockquote>埃尔克说：“初级疫苗接种——两剂疫苗接种，现在被称为三剂疫苗接种——的市场并不满意。”</blockquote>&#34;It&#39;s not exclusively low income countries, because high income countries need this. We need to get past the vaccine hesitancy,&#34; he added.<blockquote>“这不仅仅是低收入国家，因为高收入国家需要这个。我们需要克服疫苗犹豫，”他补充道。</blockquote>If the definition for &#39;fully-vaccinated&#39; changes to three doses, for both Novavax and mRNA vaccines, it could mean a complete reset in vaccination completions globally.<blockquote>如果Novavax和mRNA疫苗的“完全接种”定义更改为三剂，这可能意味着全球疫苗接种完成量的完全重置。</blockquote>Erck, who spoke at the JPMorgan annual health care conference this week, says the company is going to meet a production speed of 200 million doses per month by the end of the first quarter.<blockquote>埃尔克本周在摩根大通年度医疗保健会议上发表讲话时表示，该公司将在第一季度末达到每月2亿剂的生产速度。</blockquote>It has already begun shipments to Europe, which should total 27 million by the end of the first quarter, as well as a batch of 10 million doses to Indonesia — the site of its first shots in arms.<blockquote>它已经开始向欧洲发货，到第一季度末，总量将达到2700万剂，并向印度尼西亚发货1000万剂，印度尼西亚是它第一次打响武器的地方。</blockquote>Chief commercial officer John Trizzino told Yahoo Finance that Novavax wasn&#39;t going to provide specific guidance on the total number of doses for the year, largely because it is still waiting for more authorizations to come through, which would impact the total doses.<blockquote>首席商务官John Trizzino告诉雅虎财经，Novavax不会就今年的总剂量提供具体指导，主要是因为它仍在等待更多授权的通过，这将影响总剂量。</blockquote>As of Tuesday, Novavax has received use authorization in Indonesia, India, Europe and the Philippines, and emergency use listing from the World Health Organization. It is still awaiting authorization in South Africa, Australia, New Zealand, Singapore, Japan, UAE, U.K. and Canada. It is also waiting to get the green light to file for emergency use with the U.S. Food and Drug Administration, after submitting the necessary data at the end of 2021.<blockquote>截至周二，Novavax已获得印度尼西亚、印度、欧洲和菲律宾的使用授权，以及世界卫生组织的紧急使用清单。它仍在等待南非、澳大利亚、新西兰、新加坡、日本、阿联酋、英国和加拿大的授权。它还在等待向美国申请紧急使用的批准。食品药品监督管理局，在2021年底提交必要数据后。</blockquote>Through the WHO emergency listing, the company&#39;s vaccine is now available to 170 countries.<blockquote>通过世卫组织紧急上市，该公司的疫苗现已可供170个国家使用。</blockquote>&#34;We worked really hard over the past two years ... and now it&#39;s time to introduce our product to the world,&#34; Trizzino said.<blockquote>“过去两年我们非常努力……现在是时候向世界介绍我们的产品了，”特里齐诺说。</blockquote>Manufacturing hurdles<blockquote>制造障碍</blockquote>Novavax was a struggling late-stage biotech when the pandemic started, but it pivoted to focus on the pandemic with the help of global philanthropies and the U.S. government.<blockquote>当疫情开始时，Novavax是一家苦苦挣扎的后期生物技术公司，但在全球慈善机构和美国政府的帮助下，它转向专注于疫情。</blockquote>The company was working on a Phase 3 clinical trial for its flu vaccine and had failed to bring an RSV vaccine to market.<blockquote>该公司正在进行流感疫苗的3期临床试验，但未能将RSV疫苗推向市场。</blockquote>&#34;We, because of our RSV failures prior to that, we basically started with no manufacturing capacity. So, you&#39;re starting out in the hole, if you will, and we had to scale up very, very quickly,&#34; Trizzino said.<blockquote>“由于在此之前的RSV故障，我们基本上一开始就没有制造能力。所以，如果你愿意的话，你就从洞里开始，我们必须非常非常快地扩大规模，”特里齐诺说。</blockquote>The company&#39;s manufacturing problems contributed significantly to a delayed timeline in the past year. Trizzino said it was a significant challenge to have to manage eight global sites at one time.<blockquote>该公司的制造问题在很大程度上导致了过去一年的时间表推迟。Trizzino表示，必须同时管理八个全球站点是一个重大挑战。</blockquote>&#34;Why didn&#39;t we just focus on one facility and slam dunk it? Well, what would have been the right facility to pick? So, it was more effort than we had assumed to tech transfer to multiple facilities,&#34; he said.<blockquote>“为什么我们不专注于一个设施并大功告成呢？那么，选择什么设施才是正确的？因此，将技术转移到多个设施比我们想象的要付出更多的努力，”他说。</blockquote>In addition, the vaccine platform, while it offers easy to store and transport benefits, is complicated to make.<blockquote>此外，疫苗平台虽然具有易于储存和运输的优点，但制造起来很复杂。</blockquote>&#34;It&#39;s a complicated assay, and we underestimated what it would take to develop those assays,&#34; Trizzino said.<blockquote>“这是一种复杂的检测方法，我们低估了开发这些检测方法所需的费用，”特里齐诺说。</blockquote>Normally, it would have taken the company four to six years to scale up to where it has in the past two, he said.<blockquote>他说，通常情况下，该公司需要四到六年的时间才能扩大到过去两年的规模。</blockquote>Now, a partnership with the Serum Institute of India — which is also producing AstraZeneca&#39;s (AZN) vaccine— is helping the company make up for lost time.<blockquote>现在，与印度血清研究所（该研究所也生产阿斯利康（AZN）疫苗）的合作正在帮助该公司弥补失去的时间。</blockquote>In fact, if the vaccine is authorized in the U.S., it will be based off of the same data sent to other global health authorities, relying on the Serum Institute&#39;s manufacturing quality for doses.<blockquote>事实上，如果该疫苗在美国获得授权，它将基于发送给其他全球卫生当局的相同数据，依赖于血清研究所的剂量制造质量。</blockquote>&#34;So it would be Serum product that we would use in the U.S.,&#34; Trizzino said, noting that while the company is U.S.-based, its &#34;success or failure as a company...is not exclusively based in the U.S.&#34;<blockquote>特里齐诺说：“因此，我们将在美国使用血清产品。”他指出，虽然该公司总部位于美国，但其“作为一家公司的成功或失败……并不完全取决于美国。”</blockquote>Global vaccine market<blockquote>全球疫苗市场</blockquote>Trizzino said that the company&#39;s global focus does not mean the company will be only a provider to low income countries.<blockquote>Trizzino表示，该公司专注于全球并不意味着该公司将只是低收入国家的供应商。</blockquote>&#34;People misunderstand the market. It&#39;s not the typical vaccine launch where in year one we get launched in the U.S., and two or three years later it gets launched in Europe, and three to five years later it gets launched to the rest of the world. It&#39;s all at once,&#34; Trizzino said.<blockquote>“人们误解了市场。这不是典型的疫苗发布，第一年我们在美国上市，两三年后在欧洲上市，三到五年后在世界其他地方上市。这一切都是一次性的，”特里齐诺说。</blockquote>The company lost an opportunity to play a major role in the initial wave of vaccines in the U.S., but it still has a small market — as the country hovers at 66%of the eligible population fully vaccinated — as well opportunity globally.<blockquote>该公司失去了在美国第一波疫苗中发挥重要作用的机会，但它仍然有一个小市场——因为该国完全接种疫苗的合格人口的比例徘徊在66%——以及全球机会。</blockquote>Trizzino said that represents a 180 million dose opportunity in primary doses alone in the U.S. Add to that primary doses and boosters globally and the total is a 4 billion dose opportunity.<blockquote>Trizzino表示，仅在美国，仅初级剂量就有1.8亿剂的机会。再加上全球范围内的初级剂量和加强剂量，总共有40亿剂的机会。</blockquote>The potential doesn&#39;t stop there, Trizzino said, noting there could be additional boosters or annual revaccination on the table.<blockquote>Trizzino说，潜力还不止于此，并指出可能会有额外的加强剂或每年重新接种疫苗。</blockquote>&#34;Now, we&#39;re not saying we&#39;re going to capture all that. But what people should take away is that the trend line is that there&#39;s an increase in demand for vaccines, not a decrease,&#34; Trizzino added.<blockquote>“现在，我们并不是说我们会抓住所有这些。但人们应该记住的是，趋势线是对疫苗的需求增加，而不是减少，”特里齐诺补充道。</blockquote>The pricing strategy, meanwhile, does not reflects traditional tiered rollout of vaccines, where the U.S. can end up paying double what Europe pays. Instead, the pricing is based on a country&#39;s ability to pay.<blockquote>与此同时，定价策略并没有反映传统的疫苗分级推出，美国最终可能支付欧洲两倍的费用。相反，定价是基于一个国家的支付能力。</blockquote>&#34;Basically, Europe and the U.S. are paying the same price for doses right now. So people kind of need to reset their expectations about the way that they think about the commercial market, and what the demand profile looks like,&#34; Trizzino said.<blockquote>“基本上，欧洲和美国目前为剂量支付的价格相同。因此，人们需要重新设定他们对商业市场的看法以及需求状况的预期，”特里齐诺说。</blockquote></body></html><blockquote></blockquote>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Novavax CEO: 'We're Going to Make a Significant Impact on This COVID Pandemic'<blockquote>Novavax首席执行官：“我们将对这场新冠疫情产生重大影响”</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNovavax CEO: 'We're Going to Make a Significant Impact on This COVID Pandemic'<blockquote>Novavax首席执行官：“我们将对这场新冠疫情产生重大影响”</blockquote>\n</h2>\n<h4 class=\"meta\">\n\nYahoo Finance2022-01-13 08:59\n\n</h4>\n</header>\n<article>\n<html><head></head><body>Novavax (NVAX) is waiting for its COVID-19 vaccine to be authorized in the U.S., but with authorizations now in three major markets globally, the biotech company says it&#39;s making its mark on the pandemic.<blockquote><html><head></head><body>Novavax(NVAX)正在等待其COVID-19疫苗在美国获得授权，但随着目前已在全球三个主要市场获得授权，这家生物技术公司表示，它正在这一流行病上留下印记。</body></html></blockquote>&#34;We&#39;re going to make a significant impact on this Covid pandemic,&#34; CEO Stanley Erck told Yahoo Finance Tuesday.<blockquote>首席执行官斯坦利·埃尔克周二对雅虎财经表示：“我们将对这场新冠疫情产生重大影响。”</blockquote>&#34;The market for primary vaccination — two-dose vaccination which is now being talked about as three-dose vaccination — is unsatisfied,&#34; Erck said.<blockquote>埃尔克说：“初级疫苗接种——两剂疫苗接种，现在被称为三剂疫苗接种——的市场并不满意。”</blockquote>&#34;It&#39;s not exclusively low income countries, because high income countries need this. We need to get past the vaccine hesitancy,&#34; he added.<blockquote>“这不仅仅是低收入国家，因为高收入国家需要这个。我们需要克服疫苗犹豫，”他补充道。</blockquote>If the definition for &#39;fully-vaccinated&#39; changes to three doses, for both Novavax and mRNA vaccines, it could mean a complete reset in vaccination completions globally.<blockquote>如果Novavax和mRNA疫苗的“完全接种”定义更改为三剂，这可能意味着全球疫苗接种完成量的完全重置。</blockquote>Erck, who spoke at the JPMorgan annual health care conference this week, says the company is going to meet a production speed of 200 million doses per month by the end of the first quarter.<blockquote>埃尔克本周在摩根大通年度医疗保健会议上发表讲话时表示，该公司将在第一季度末达到每月2亿剂的生产速度。</blockquote>It has already begun shipments to Europe, which should total 27 million by the end of the first quarter, as well as a batch of 10 million doses to Indonesia — the site of its first shots in arms.<blockquote>它已经开始向欧洲发货，到第一季度末，总量将达到2700万剂，并向印度尼西亚发货1000万剂，印度尼西亚是它第一次打响武器的地方。</blockquote>Chief commercial officer John Trizzino told Yahoo Finance that Novavax wasn&#39;t going to provide specific guidance on the total number of doses for the year, largely because it is still waiting for more authorizations to come through, which would impact the total doses.<blockquote>首席商务官John Trizzino告诉雅虎财经，Novavax不会就今年的总剂量提供具体指导，主要是因为它仍在等待更多授权的通过，这将影响总剂量。</blockquote>As of Tuesday, Novavax has received use authorization in Indonesia, India, Europe and the Philippines, and emergency use listing from the World Health Organization. It is still awaiting authorization in South Africa, Australia, New Zealand, Singapore, Japan, UAE, U.K. and Canada. It is also waiting to get the green light to file for emergency use with the U.S. Food and Drug Administration, after submitting the necessary data at the end of 2021.<blockquote>截至周二，Novavax已获得印度尼西亚、印度、欧洲和菲律宾的使用授权，以及世界卫生组织的紧急使用清单。它仍在等待南非、澳大利亚、新西兰、新加坡、日本、阿联酋、英国和加拿大的授权。它还在等待向美国申请紧急使用的批准。食品药品监督管理局，在2021年底提交必要数据后。</blockquote>Through the WHO emergency listing, the company&#39;s vaccine is now available to 170 countries.<blockquote>通过世卫组织紧急上市，该公司的疫苗现已可供170个国家使用。</blockquote>&#34;We worked really hard over the past two years ... and now it&#39;s time to introduce our product to the world,&#34; Trizzino said.<blockquote>“过去两年我们非常努力……现在是时候向世界介绍我们的产品了，”特里齐诺说。</blockquote>Manufacturing hurdles<blockquote>制造障碍</blockquote>Novavax was a struggling late-stage biotech when the pandemic started, but it pivoted to focus on the pandemic with the help of global philanthropies and the U.S. government.<blockquote>当疫情开始时，Novavax是一家苦苦挣扎的后期生物技术公司，但在全球慈善机构和美国政府的帮助下，它转向专注于疫情。</blockquote>The company was working on a Phase 3 clinical trial for its flu vaccine and had failed to bring an RSV vaccine to market.<blockquote>该公司正在进行流感疫苗的3期临床试验，但未能将RSV疫苗推向市场。</blockquote>&#34;We, because of our RSV failures prior to that, we basically started with no manufacturing capacity. So, you&#39;re starting out in the hole, if you will, and we had to scale up very, very quickly,&#34; Trizzino said.<blockquote>“由于在此之前的RSV故障，我们基本上一开始就没有制造能力。所以，如果你愿意的话，你就从洞里开始，我们必须非常非常快地扩大规模，”特里齐诺说。</blockquote>The company&#39;s manufacturing problems contributed significantly to a delayed timeline in the past year. Trizzino said it was a significant challenge to have to manage eight global sites at one time.<blockquote>该公司的制造问题在很大程度上导致了过去一年的时间表推迟。Trizzino表示，必须同时管理八个全球站点是一个重大挑战。</blockquote>&#34;Why didn&#39;t we just focus on one facility and slam dunk it? Well, what would have been the right facility to pick? So, it was more effort than we had assumed to tech transfer to multiple facilities,&#34; he said.<blockquote>“为什么我们不专注于一个设施并大功告成呢？那么，选择什么设施才是正确的？因此，将技术转移到多个设施比我们想象的要付出更多的努力，”他说。</blockquote>In addition, the vaccine platform, while it offers easy to store and transport benefits, is complicated to make.<blockquote>此外，疫苗平台虽然具有易于储存和运输的优点，但制造起来很复杂。</blockquote>&#34;It&#39;s a complicated assay, and we underestimated what it would take to develop those assays,&#34; Trizzino said.<blockquote>“这是一种复杂的检测方法，我们低估了开发这些检测方法所需的费用，”特里齐诺说。</blockquote>Normally, it would have taken the company four to six years to scale up to where it has in the past two, he said.<blockquote>他说，通常情况下，该公司需要四到六年的时间才能扩大到过去两年的规模。</blockquote>Now, a partnership with the Serum Institute of India — which is also producing AstraZeneca&#39;s (AZN) vaccine— is helping the company make up for lost time.<blockquote>现在，与印度血清研究所（该研究所也生产阿斯利康（AZN）疫苗）的合作正在帮助该公司弥补失去的时间。</blockquote>In fact, if the vaccine is authorized in the U.S., it will be based off of the same data sent to other global health authorities, relying on the Serum Institute&#39;s manufacturing quality for doses.<blockquote>事实上，如果该疫苗在美国获得授权，它将基于发送给其他全球卫生当局的相同数据，依赖于血清研究所的剂量制造质量。</blockquote>&#34;So it would be Serum product that we would use in the U.S.,&#34; Trizzino said, noting that while the company is U.S.-based, its &#34;success or failure as a company...is not exclusively based in the U.S.&#34;<blockquote>特里齐诺说：“因此，我们将在美国使用血清产品。”他指出，虽然该公司总部位于美国，但其“作为一家公司的成功或失败……并不完全取决于美国。”</blockquote>Global vaccine market<blockquote>全球疫苗市场</blockquote>Trizzino said that the company&#39;s global focus does not mean the company will be only a provider to low income countries.<blockquote>Trizzino表示，该公司专注于全球并不意味着该公司将只是低收入国家的供应商。</blockquote>&#34;People misunderstand the market. It&#39;s not the typical vaccine launch where in year one we get launched in the U.S., and two or three years later it gets launched in Europe, and three to five years later it gets launched to the rest of the world. It&#39;s all at once,&#34; Trizzino said.<blockquote>“人们误解了市场。这不是典型的疫苗发布，第一年我们在美国上市，两三年后在欧洲上市，三到五年后在世界其他地方上市。这一切都是一次性的，”特里齐诺说。</blockquote>The company lost an opportunity to play a major role in the initial wave of vaccines in the U.S., but it still has a small market — as the country hovers at 66%of the eligible population fully vaccinated — as well opportunity globally.<blockquote>该公司失去了在美国第一波疫苗中发挥重要作用的机会，但它仍然有一个小市场——因为该国完全接种疫苗的合格人口的比例徘徊在66%——以及全球机会。</blockquote>Trizzino said that represents a 180 million dose opportunity in primary doses alone in the U.S. Add to that primary doses and boosters globally and the total is a 4 billion dose opportunity.<blockquote>Trizzino表示，仅在美国，仅初级剂量就有1.8亿剂的机会。再加上全球范围内的初级剂量和加强剂量，总共有40亿剂的机会。</blockquote>The potential doesn&#39;t stop there, Trizzino said, noting there could be additional boosters or annual revaccination on the table.<blockquote>Trizzino说，潜力还不止于此，并指出可能会有额外的加强剂或每年重新接种疫苗。</blockquote>&#34;Now, we&#39;re not saying we&#39;re going to capture all that. But what people should take away is that the trend line is that there&#39;s an increase in demand for vaccines, not a decrease,&#34; Trizzino added.<blockquote>“现在，我们并不是说我们会抓住所有这些。但人们应该记住的是，趋势线是对疫苗的需求增加，而不是减少，”特里齐诺补充道。</blockquote>The pricing strategy, meanwhile, does not reflects traditional tiered rollout of vaccines, where the U.S. can end up paying double what Europe pays. Instead, the pricing is based on a country&#39;s ability to pay.<blockquote>与此同时，定价策略并没有反映传统的疫苗分级推出，美国最终可能支付欧洲两倍的费用。相反，定价是基于一个国家的支付能力。</blockquote>&#34;Basically, Europe and the U.S. are paying the same price for doses right now. So people kind of need to reset their expectations about the way that they think about the commercial market, and what the demand profile looks like,&#34; Trizzino said.<blockquote>“基本上，欧洲和美国目前为剂量支付的价格相同。因此，人们需要重新设定他们对商业市场的看法以及需求状况的预期，”特里齐诺说。</blockquote></body></html><blockquote></blockquote>\n<div class=\"bt-text\">\n\n\n 来源：<a href=\"https://finance.yahoo.com/news/novavax-ceo-were-going-to-make-a-significant-impact-on-this-covid-pandemic-195631610.html\">Yahoo Finance</a>\n为提升您的阅读体验，我们对本页面进行了排版优化\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NVAX":"诺瓦瓦克斯医药"},"source_url":"https://finance.yahoo.com/news/novavax-ceo-were-going-to-make-a-significant-impact-on-this-covid-pandemic-195631610.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1107505154","content_text":"Novavax (NVAX) is waiting for its COVID-19 vaccine to be authorized in the U.S., but with authorizations now in three major markets globally, the biotech company says it's making its mark on the pandemic.\"We're going to make a significant impact on this Covid pandemic,\" CEO Stanley Erck told Yahoo Finance Tuesday.\"The market for primary vaccination — two-dose vaccination which is now being talked about as three-dose vaccination — is unsatisfied,\" Erck said.\"It's not exclusively low income countries, because high income countries need this. We need to get past the vaccine hesitancy,\" he added.If the definition for 'fully-vaccinated' changes to three doses, for both Novavax and mRNA vaccines, it could mean a complete reset in vaccination completions globally.Erck, who spoke at the JPMorgan annual health care conference this week, says the company is going to meet a production speed of 200 million doses per month by the end of the first quarter.It has already begun shipments to Europe, which should total 27 million by the end of the first quarter, as well as a batch of 10 million doses to Indonesia — the site of its first shots in arms.Chief commercial officer John Trizzino told Yahoo Finance that Novavax wasn't going to provide specific guidance on the total number of doses for the year, largely because it is still waiting for more authorizations to come through, which would impact the total doses.As of Tuesday, Novavax has received use authorization in Indonesia, India, Europe and the Philippines, and emergency use listing from the World Health Organization. It is still awaiting authorization in South Africa, Australia, New Zealand, Singapore, Japan, UAE, U.K. and Canada. It is also waiting to get the green light to file for emergency use with the U.S. Food and Drug Administration, after submitting the necessary data at the end of 2021.Through the WHO emergency listing, the company's vaccine is now available to 170 countries.\"We worked really hard over the past two years ... and now it's time to introduce our product to the world,\" Trizzino said.Manufacturing hurdlesNovavax was a struggling late-stage biotech when the pandemic started, but it pivoted to focus on the pandemic with the help of global philanthropies and the U.S. government.The company was working on a Phase 3 clinical trial for its flu vaccine and had failed to bring an RSV vaccine to market.\"We, because of our RSV failures prior to that, we basically started with no manufacturing capacity. So, you're starting out in the hole, if you will, and we had to scale up very, very quickly,\" Trizzino said.The company's manufacturing problems contributed significantly to a delayed timeline in the past year. Trizzino said it was a significant challenge to have to manage eight global sites at one time.\"Why didn't we just focus on one facility and slam dunk it? Well, what would have been the right facility to pick? So, it was more effort than we had assumed to tech transfer to multiple facilities,\" he said.In addition, the vaccine platform, while it offers easy to store and transport benefits, is complicated to make.\"It's a complicated assay, and we underestimated what it would take to develop those assays,\" Trizzino said.Normally, it would have taken the company four to six years to scale up to where it has in the past two, he said.Now, a partnership with the Serum Institute of India — which is also producing AstraZeneca's (AZN) vaccine— is helping the company make up for lost time.In fact, if the vaccine is authorized in the U.S., it will be based off of the same data sent to other global health authorities, relying on the Serum Institute's manufacturing quality for doses.\"So it would be Serum product that we would use in the U.S.,\" Trizzino said, noting that while the company is U.S.-based, its \"success or failure as a company...is not exclusively based in the U.S.\"Global vaccine marketTrizzino said that the company's global focus does not mean the company will be only a provider to low income countries.\"People misunderstand the market. It's not the typical vaccine launch where in year one we get launched in the U.S., and two or three years later it gets launched in Europe, and three to five years later it gets launched to the rest of the world. It's all at once,\" Trizzino said.The company lost an opportunity to play a major role in the initial wave of vaccines in the U.S., but it still has a small market — as the country hovers at 66%of the eligible population fully vaccinated — as well opportunity globally.Trizzino said that represents a 180 million dose opportunity in primary doses alone in the U.S. Add to that primary doses and boosters globally and the total is a 4 billion dose opportunity.The potential doesn't stop there, Trizzino said, noting there could be additional boosters or annual revaccination on the table.\"Now, we're not saying we're going to capture all that. But what people should take away is that the trend line is that there's an increase in demand for vaccines, not a decrease,\" Trizzino added.The pricing strategy, meanwhile, does not reflects traditional tiered rollout of vaccines, where the U.S. can end up paying double what Europe pays. Instead, the pricing is based on a country's ability to pay.\"Basically, Europe and the U.S. are paying the same price for doses right now. So people kind of need to reset their expectations about the way that they think about the commercial market, and what the demand profile looks like,\" Trizzino said.","news_type":1,"symbols_score_info":{"NVAX":0.9}},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"}],"hasMoreComments":true,"newsSizeData":{"likeSize":12,"commentSize":3,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"isCrawlerRequest":true}